Cardiovascular disease in rheumatoid arthritis: medications and risk factors in China
- 470 Downloads
This study aims to assess the risk factors of cardiovascular disease (CVD) and to determine the association of traditional and biologic disease-modifying anti-rheumatic drugs (DMARDs) with risk for CVD in Chinese rheumatoid arthritis (RA) patients. A cross-sectional cohort of 2013 RA patients from 21 hospitals around China was established. Medical history of CVD was documented. The patients’ social background, clinical manifestations, comorbidities, and medications were also collected. Of the 2013 patients, 256 had CVD with an incidence of 12.7%. Compared with non-CVD controls, RA patients with CVD had a significantly advanced age, long-standing median disease duration, more often male and more deformity joints. Patients with CVD also had higher rates of smoking, rheumatoid nodules, interstitial lung disease, and anemia. The prevalence of comorbidities, including hypothyroidism, diabetes mellitus (DM), hypertension, and hyperlipidemia, was also significant higher in the CVD group. In contrast, patients treated with methotrexate, hydroxychloroquine (HCQ), and TNF blockers had lower incidence of CVD. The multivariate analysis showed that the use of HCQ was a protective factor of CVD, while hypertension, hyperlipidemia, and interstitial lung disease were independent risk factors of CVD. Our study shows that the independent risk factors of CVD include hypertension, hyperlipidemia, and interstitial lung disease. HCQ reduces the risk of CVD in patients with RA.
KeywordsCardiovascular disease Rheumatoid arthritis Risk factor
We are very grateful to the patients and their families for their cooperation and for giving consent to participate in this study.
Compliance with ethical standards
The study was approved by the Ethics Committee of Peking University People’s Hospital, and informed written consents were obtained from all study participants (FWA00001384).
Supported by National High Technology Research and Development Program of China (973 Program, 2012CB517700) and National Natural Science Foundation of China (NSFC, No. 81202297)
- 3.Gonzalez A, Maradit KH, Crowson CS, Ballman KV, Roger VL, Jacobsen SJ, O’Fallon WM, Gabriel SE (2008) Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients. Ann Rheum Dis 67:64–69CrossRefPubMedGoogle Scholar
- 4.Pham T, Gossec L, Constantin A, Pavy S, Bruckert E, Cantagrel A, Combe B, Flipo RM, Goupille P, Le LX, Mariette X, Puechal X, Schaeverbeke T, Sibilia J, Tebib J, Wendling D, Dougados M (2006) Cardiovascular risk and rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine 73:379–387CrossRefPubMedGoogle Scholar
- 6.Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK, McInnes IB, Haentzschel H, Gonzalez-Gay MA, Provan S, Semb A, Sidiropoulos P, Kitas G, Smulders YM, Soubrier M, Szekanecz Z, Sattar N, Nurmohamed MT (2010) EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69:325–331CrossRefPubMedGoogle Scholar
- 12.Bili A, Tang X, Pranesh S, Bozaite R, DO SJ, Antohe JL, Kirchner HL, Wasko MC (2013) TNF-alpha inhibitor use and decreased risk for incident coronary events in rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 66:355–363.Google Scholar
- 14.Rodriguez-Rodriguez L, Gonzalez-Juanatey C, Palomino-Morales R, Vazquez-Rodriguez TR, Miranda-Filloy JA, Fernandez-Gutierrez B, Llorca J, Martin J, Gonzalez-Gay MA (2011) TNFA -308 (rs1800629) polymorphism is associated with a higher risk of cardiovascular disease in patients with rheumatoid arthritis. Atherosclerosis 216:125–130CrossRefPubMedGoogle Scholar
- 15.van Halm VP, Peters MJ, Voskuyl AE, Boers M, Lems WF, Visser M, Stehouwer CD, Spijkerman AM, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Smulders YM, Dijkmans BA, Nurmohamed MT (2009) Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation. Ann Rheum Dis 68:1395–1400CrossRefPubMedGoogle Scholar
- 16.(1997) The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 157:2413–2446Google Scholar
- 18.World Health Organization Western Pacific Region/IASO/IOTF (2000) The Asia–Pacific perspective: redefining obesity and its treatment. SydneyGoogle Scholar
- 21.Toms TE, Panoulas VF, Douglas KM, Griffiths H, Sattar N, Smith JP, Symmons DP, Nightingale P, Metsios GS, Kitas GD (2010) Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk. Ann Rheum Dis 69:683–688CrossRefPubMedGoogle Scholar
- 24.Chung CP, Giles JT, Kronmal RA, Post WS, Gelber AC, Petri M, Szklo M, Detrano R, Budoff MJ, Blumenthal RS, Ouyang P, Bush D, Bathon JM (2013) Progression of coronary artery atherosclerosis in rheumatoid arthritis: comparison with participants from the Multi-Ethnic Study of Atherosclerosis. Arthritis Res Ther 15:R134CrossRefPubMedPubMedCentralGoogle Scholar
- 34.Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B (2015) The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 74:480–489CrossRefPubMedPubMedCentralGoogle Scholar
- 35.Solomon DH, Curtis JR, Saag KG, Lii J, Chen L, Harrold LR, Herrinton LJ, Graham DJ, Kowal MK, Kuriya B, Liu L, Griffin MR, Lewis JD, Rassen JA (2013) Cardiovascular risk in rheumatoid arthritis: comparing TNF-alpha blockade with nonbiologic DMARDs. Am J Med 126(730):e9-730–e9-e17Google Scholar
- 40.Gonzalez-Juanatey C, Llorca J, Vazquez-Rodriguez TR, Diaz-Varela N, Garcia-Quiroga H, Gonzalez-Gay MA (2008) Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy. Arthritis Rheum 59:1821–1824CrossRefPubMedGoogle Scholar